Response and outcomes to nilotinib at 24 months in patients with imatinib-resistant chronic myeloid leukemia in chronic phase and accelerated phase with and without BCR-ABL mutations
Response and outcomes to nilotinib at 24 months in patients with imatinib-resistant chronic myeloid leukemia in chronic phase and accelerated phase with and without BCR-ABL mutations
[version 1; not peer reviewed]Radich: Novartis Consultancy, Honoraria, Research Funding. Hochhaus: Novartis Research Funding. Branford: Novartis Pharmaceuticals Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Bristol-Myers Squib (BMS)b Honoraria, Research Funding. Shou: Novartis Employment. Haque: Novartis Employment. Woodman: Novartis Employment. Kantarjian: Novartis Research Funding. Hughes: BMS Advisor, Honoraria, Research Funding; Novartis Advisor, Honoraria, Research Funding. Kim: Novartis Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; BMS Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Wyeth Research Funding. Saglio: Novartis Consultancy, Speakers Bureau; BMS Consultancy, Speakers Bureau.
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
All commenters must hold a formal affiliation as per our Policies. The information that you give us will be displayed next to your comment.
User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the User Comment Terms and Conditions. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.
Use of this website is subject to the F1000 Research Limited (F1000) General Terms and Conditions.
Submission of user comments to this website is subject to additional Terms and Conditions. By clicking "I accept the User Comment Terms and Conditions" before you submit your first comment, you agree to be bound by these conditions every time you submit a comment.
Terms relating to user comments